Trials
3 active
28 in total · 4 in the EU
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “Participants will receive a single injection containing variant-adapted BNT162b2 on Day 1.”In the company’s words, NCT07730450 on ClinicalTrials.gov
- Tested for
- COVID-19 Vaccines (2 trials)
- Main trialPhase 4
- “The purpose of this study is to learn about the safety and effects of an updated COVID-19 vaccine (called BNT162b2) in adults 18 to 64 years of age. This study is seeking participants who: * are medically stable * have not had a recent COVID-19 infection * have not had a recent vaccination * do not have medical conditions that increase their risk of complications from COVID-19 All participants in this study will randomly receive 1 injection into their arm of either: * BNT162b2 vaccine which targets COVID-19 and is selected for the 2026-2027 COVID-19 season, or * Tdap vaccine which targets…”In the company’s words, NCT07730450 on ClinicalTrials.gov
- Other names
- Comirnaty
Other drugs for COVID-19 Vaccines
- MaravirocHealthBio, Inc. · Phase 2/3
- REGENECYTEStemCyte, Inc. · Phase 3
- VYD2311Invivyd, Inc. · Phase 3
- SecutrelvirShionogi · Phase 3
- IbuzatrelvirPfizer · Phase 3
- TozorakimabAstraZeneca · Phase 3
Coming up2
- 12 Apr 2027Phase 3 trial completes · ClinicalTrials.gov
- 20 Aug 2027Phase 4 trial completes · ClinicalTrials.gov
Changes2
Last 90 days- 18 NovStatus changed: Recruiting to Active, not recruiting · ClinicalTrials.gov NCT07798648
- 18 NovCompletion date moved: 2027-04-21 to 2027-04-12 · ClinicalTrials.gov NCT07798648
Trials28
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 4Recruiting | 20 Aug 2027 | A Study to Learn About a COVID-19 Vaccine in Healthy Adults 18 Through 64 Years of Age | |
| Phase 3Active, not recruiting | 12 Apr 2027 | A Study of COVID-19 Vaccine(s) in Children and Adults | |
| Phase 4Completed | 25 Nov 2021 | Study to Evaluate the Safety, Tolerability, and Immunogenicity of an RNA Vaccine Candidate Against COVID-19 in Healthy Japanese Adults | |
| Phase 3Completed | 22 Jul 2021 | A Phase 3 Study to Evaluate the Safety, Tolerability, and Immunogenicity of Multiple Production Lots and Dose Levels of BNT162b2 RNA-Based COVID-19 Vaccines Against COVID-19 in Healthy Participants | |
| Phase 3Completed | 1 Dec 2021 | A Study to Evaluate Safety, Tolerability, & Immunogenicity of Multiple Formulations of BNT162b2 Against COVID-19 in Healthy Adults | |
| Phase 3Completed | 5 Oct 2022 | Safety and Immunogenicity of BNT162b2 Coadministered With SIIV in Adults 18 Through 64 Years of Age | |
| Phase 3Completed | 25 May 2023 | To Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of BNT162b2 Boosting Strategies Against COVID-19 in Participants ≥12 Years of Age. | |
| Phase 3Completed | 4 Oct 2023 | Study to Evaluate the Safety, Tolerability, and Immunogenicity of an RNA Vaccine Candidate Against COVID-19 in Healthy Children | |
| Phase 3Completed | 1 May 2026 | A Study to Learn About COVID-19 RNA-Based Variant-Adapted Vaccine Candidate(s) Against SARS-CoV-2 in Participants Ages 12 Through 64 Years Considered at Higher Risk of Severe COVID-19, and Participants Ages ≥65 Years | |
| Phase 3Completed | 10 Jul 2026 | A Study to Learn About Variant-Adapted COVID-19 RNA Vaccine Candidate(s) in Healthy Children | |
| Phase 3Completed | 24 Jul 2026 | A Study to Learn About BNT162b2 (LP.8.1)-Adapted Vaccine Against SARS-CoV-2 in Children 5 Through 11 Years of Age That Are Considered at Higher Risk of Severe COVID-19 | |
| Phase 3Completed | 22 Sep 2026 | A Study to Learn About a COVID-19 Vaccine in Healthy Adults 50 Through 64 Years of Age | |
| Phase 2/3Completed | 15 Jul 2022 | To Evaluate the Safety, Tolerability, and Immunogenicity of BNT162b2 Against COVID-19 in Healthy Pregnant Women 18 Years of Age and Older | |
| Phase 2/3Completed | 10 Feb 2023 | Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals | |
| Phase 2/3Completed | 26 Mar 2024 | A Study to Learn About New COVID-19 RNA Vaccine Candidates in COVID-19 Vaccine-Experienced Healthy Individuals | |
| Phase 2/3Completed | 13 Mar 2025 | A Study to Learn About New COVD-19 RNA Vaccine Candidates for New Variants in Healthy Individuals | |
| Phase 2Completed | 7 Feb 2021 | Safety and Immunogenicity of SARS-CoV-2 mRNA Vaccine (BNT162b2) in Chinese Healthy Population | |
| Phase 2Completed | 14 Apr 2022 | A Trial Investigating the Safety and Effects of One or Two Additional Doses of Comirnaty or One Dose of BNT162b2s01 in BNT162-01 or BNT162-04 Trial Subjects | |
| Phase 2Completed | 23 Jul 2023 | Study to Evaluate Safety, Tolerability & Immunogenicity of BNT162b2 in Immunocompromised Participants ≥2 Years | |
| Phase 2Completed | 16 Aug 2023 | Safety and Immunogenicity of RNA-based Vaccines Against SARS-CoV-2 Variants in Healthy Participants | |
| Phase 2Completed | 28 Dec 2023 | A Study to Evaluate the Safety, Tolerability, and Immunogenicity of Combined Modified RNA Vaccine Candidates Against COVID-19 and Influenza | |
| Phase 1/2Completed | 30 Jun 2021 | A Trial Investigating the Safety and Effects of Four BNT162 Vaccines Against COVID-19 in Healthy and Immunocompromised Adults | |
| Phase 1Completed | 22 Nov 2024 | Safety and Effects of an Investigational COVID-19 Vaccine as Booster in Healthy People | |
| Phase 1Withdrawn | 13 Jul 2026 | A Study to Learn About Bivalent COVID-19 RNA Vaccine Candidate(s) in Healthy Infants and Children | |
| Phase 2Ended | not given | Intradermal administration of a COVID-19 mRNA vaccine in elderly | |
| Phase 4Authorised | not given | Temporal kinetics of antibody and cellular response markers and relative impact of revaccination in patients recovered from COVID-19 after treatment with monoclonal antibodies | |
| Phase 2Ended | not given | CONCOMITANT ADMINISTRATION OF LICENSED VACCINES AGAINST COVID-19 AND FLU WITH OR WITHOUT MF59 ADJUVANT: A MULTI-CENTRE, RANDOMIZED, SINGLE-BLIND CLINICAL TRIAL TO ASSESS IMMUNOGENICITY IN ADULTS AGED 65 AND OVER | |
| Phase 4Ended | not given | COVID-19 vaccine immunological studies in Finland |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 20 Nov 2026 · EU trials register (CTIS) updated 20 Nov 2026 · openFDA updated 20 Nov 2026